Furthermore, a novel microfluidic device, the CTC-iChip, was used to efficiently detect and enrich CTCs using a panel of mesenchymal gene expression signatures (referred to as STEAM: SOX2, Tubulin beta-3, EGFR, A2B5, and c-MET) in the peripheral blood of GBM patients [239]. This evidence concerns the gene EGFR and glioblastoma.